On March 17, 2023, two bipartisan pieces of legislation were introduced to the U.S. House of Representatives with the goal of requiring the U.S. Food and Drug Administration (FDA) to regulate cannabidiol (CBD) products in foods and dietary supplements. 

The U.S. Food and Drug Administration (FDA) has decided that cannabidiol (CBD) products will not be regulated as a food or supplement, rather, a new approach will be developed. The agency has also denied three consumer petitions requesting that FDA allow the marketing of CBD products as dietary supplements.

A recent study has found pervasive, low levels of lead, cadmium, arsenic, mercury, and phthalates in U.S. cannabidiol products. The study also demonstrated substantial inaccuracies of product label claims for CBD potency.

The European Food Safety Authority (EFSA) announced that it cannot determine the safety of cannabidiol as a novel food, citing significant knowledge gaps and several causes for concern.